&nbsp;

Aug 2025

Drug

encorafenib

Other Name(s): Braftovi®

Quick Link(s):

Apr 2024

Drug

isatuximab

Other Name(s): Sarclisa®

Quick Link(s):

Mar 2024

Regimen

ENTR

Cancer Type:

Breast,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Lung,

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Intent: Palliative

Funding:

Exceptional Access Program

entrectinib - Treatment of patients with unresectable locally advanced, or metastatic solid extracranial tumours documented to have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, according to specific criteria

Drugs Used:

entrectinib

Quick Link(s):

Regimen Monograph

Sep 2024

Drug

sacituzumab govitecan

Other Name(s): Trodelvy®

Quick Link(s):

Jul 2025

Drug

Enhertu trastuzumab deruxtecan

Other Name(s): Enhertu®

Quick Link(s):

May 2025

Regimen

TECL; TECL(RAMP)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma

High Cost Therapy Funding Program

Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma

Drugs Used:

teclistamab

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

BORTDEXALENA+DARA; LENA+DARA(MNT)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant

ODB - General Benefit

dexamethasone

Drugs Used:

daratumumab (Unfunded),

bortezomib (Unfunded),

lenalidomide (Unfunded),

dexamethasone

Quick Link(s):

Regimen Monograph

Apr 2025

Drug

crisantaspase recombinant

Other Name(s): Rylaze™

Quick Link(s):

Jan 2024

Regimen

SELP

Cancer Type:

Endocrine,

Thyroid

Intent: Palliative

Funding:

Exceptional Access Program

selpercatinib - For the treatments of advanced or metastatic RET fusion-positive differentiated thyroid carcinoma (DTC); and unresectable advanced or metastatic RET-mutant medullary thyroid cancer (MTC)

Drugs Used:

selpercatinib